At a glance
ClinicalIndex Comparison RecordN/ACompleted· 535 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multi-Center, Longitudinal, Prospective, Observational, Multi-Cohort Study of Patients With Advanced Non-Small Cell Lung Cancer Treated With Nivolumab in France After at Least One Prior Chemotherapy-based Treatment (LIST, Lung Initiative on Sequence Therapy)
In Brief
An observational study for Lung Cancer. Completed, enrolled 535 participants across 1 site.
Detailed Summary
The purpose of this trial is to describe the following, for each cohort, in real world conditions in France: * The characteristics and treatment sequence of patients treated with nivolumab * The effectiveness of nivolumab treatment * The safety profile of nivolumab * Treatment patterns (e.g. duration of treatment, subsequent treatments) of nivolumab * The patient-reported outcomes (PRO) in patients treated with nivolumab, at baseline and during follow up using the EuroQoL-5D-3L
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsLung Cancer
CountriesFrance
Collaborators--
Timeline
N/ACompletedFinished
202120222023202420252026
First PostedAug 2020
Enrollment StartSep 2020
Primary CompletionApr 2025
TodayJul 2026
First PostedAug 5, 2020
Enrollment StartSep 28, 2020
Primary CompletionApr 18, 2025
TodayJul 2, 2026
Enrollment to primary: 4.6 yearsPosted 5.9 years ago